BECOME trial

Betaseron v. Copaxone with triple dose gado and 3T MRI. Head to head trial with combined active lesions as primary endpoint. No difference between 2 groups in 75 randomized patients. In a secondary endpoint, IFN but not GA has a drop in active lesions from pre treatment. Not clear what this means